We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+1%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$65.2B
AUM Growth
+$6.51B
(+11%)
Cap. Flow
+$6.71B
Cap. Flow
% of AUM
10.29%
Top 10 Holdings %
Top 10 Hldgs %
15.4%
Holding
2,716
New
313
Increased
1,389
Reduced
876
Closed
123
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$213M |
| 2 |
Cigna
CI
|
+$207M |
| 3 |
Comcast
CMCSA
|
+$164M |
| 4 |
Zoom
ZM
|
+$155M |
| 5 |
Johnson & Johnson
JNJ
|
+$139M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$237M |
| 2 |
TSMC
TSM
|
+$214M |
| 3 |
NVIDIA
NVDA
|
+$138M |
| 4 |
Adobe
ADBE
|
+$133M |
| 5 |
Pultegroup
PHM
|
+$124M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.59% |
| 2 | Financials | 13.87% |
| 3 | Industrials | 12.52% |
| 4 | Consumer Discretionary | 12.44% |
| 5 | Healthcare | 12.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Iovance Biotherapeutics
IOVA
$2.9B
| $92K | ﹤0.01% |
11,477
-28,534
| -71% | -$306K |
|
2502
Cardlytics
CDLX
$22.4M
| $91.9K | ﹤0.01% |
1,119
-106
| -9% | -$11.5K |
|
|
ORGN
2503
DELISTED
Origin Materials
ORGN
| $89.2K | ﹤0.01% |
3,299
+2,571
| +353% | +$68.7K |
|
2504
Redwire
RDW
$3.13B
| $89K | ﹤0.01% |
+12,415
| New | +$59.7K |
|
|
GRFS
2505
Grifois
GRFS
$5.48B
| $88.9K | ﹤0.01% |
+14,107
| New | +$98K |
|
2506
Turkcell
TKC
$4.79B
| $88.5K | ﹤0.01% |
+11,678
| New | +$76.7K |
|
|
PGRE
2507
DELISTED
Paramount Group
PGRE
| $87K | ﹤0.01% |
19,203
+1,647
| +9% | +$7.63K |
|
2508
Oric Pharmaceuticals
ORIC
$1.41B
| $86.5K | ﹤0.01% |
12,241
-2,057
| -14% | -$18.4K |
|
|
IGMS
2509
DELISTED
IGM Biosciences
IGMS
| $84K | ﹤0.01% |
+12,230
| New | +$105K |
|
2510
ESS Tech
GWH
$17.1M
| $83.6K | ﹤0.01% |
+6,817
| New | +$76.8K |
|
|
VTNR
2511
DELISTED
Vertex Energy, Inc
VTNR
| $83.5K | ﹤0.01% |
88,398
-1,228,767
| -93% | -$1.44M |
|
2512
Archer Aviation
ACHR
$4.78B
| $83.2K | ﹤0.01% |
23,648
-470
| -2% | -$1.74K |
|
|
ADAM
2513
Adamas Trust
ADAM
$880M
| $83K | ﹤0.01% |
+14,215
| New | +$91.1K |
|
2514
Precigen
PGEN
$2.51B
| $79K | ﹤0.01% |
50,002
+18,097
| +57% | +$26.3K |
|
2515
SGHC Ltd
SGHC
$6.55B
| $77.3K | ﹤0.01% |
+23,919
| New | +$80.7K |
|
2516
Outlook Therapeutics
OTLK
$215M
| $75K | ﹤0.01% |
+10,164
| New | +$81.6K |
|
|
HBI
2517
DELISTED
Hanesbrands
HBI
| $74.8K | ﹤0.01% |
15,741
+752
| +5% | +$3.69K |
|
2518
Clarus
CLAR
$145M
| $72.8K | ﹤0.01% |
10,811
-155,160
| -93% | -$1.02M |
|
2519
MiMedx Group
MDXG
$622M
| $71.8K | ﹤0.01% |
10,365
-8,039
| -44% | -$56.5K |
|
2520
Blue Ridge Bankshares
BRBS
$334M
| $71.6K | ﹤0.01% |
+27,446
| New | +$76.6K |
|
2521
CS Disco
LAW
$271M
| $71.1K | ﹤0.01% |
11,933
-9,284
| -44% | -$64.1K |
|
2522
Pulmonx
LUNG
$97.9M
| $70.1K | ﹤0.01% |
11,059
-48,671
| -81% | -$374K |
|
2523
Evolv Technologies
EVLV
$1.05B
| $69.6K | ﹤0.01% |
27,312
-409,686
| -94% | -$1.36M |
|
2524
PLAYSTUDIOS Inc
MYPS
$86.3M
| $67.7K | ﹤0.01% |
+32,716
| New | +$77K |
|
|
LICY
2525
DELISTED
Li-Cycle Holdings Corp.
LICY
| $67.4K | ﹤0.01% |
10,318
+7,988
| +343% | +$44.1K |
|
Similar funds
VGA
AQR Capital Management's Q2 2024 Portfolio in Review
As of Q2 2024, AQR Capital Management held 2,716 positions worth $65.2B, up 11% from $58.7B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
AQR Capital Management deployed $6.71B of net new capital in Q2 2024, opening 313 new positions and adding to 1,389 existing holdings. Its largest new stake was Solventum: 1,217,998 shares worth $62.6M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 25% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Humana, an estimated $237M trimmed.
- AQR Capital Management's largest Q2 2024 buy was Solventum: 1,217,998 shares worth $62.6M.
- AQR Capital Management added most to ExxonMobil in Q2 2024, an estimated $213M increase.
- AQR Capital Management's biggest Q2 2024 reduction was Humana, cutting an estimated $237M.
- AQR Capital Management fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $27.7M.
- AQR Capital Management's ten largest holdings make up 15% of its $65.2B portfolio in Q2 2024.
- AQR Capital Management opened 313 new positions and closed 123 in Q2 2024.
- AQR Capital Management's portfolio value rose 11% quarter-over-quarter to $65.2B.
Based on AQR Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.